-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study…
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources…
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE)…
ROSCREA, Ireland and FREIBURG, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed…
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…
NDA will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or…
PALO ALTO, CA / ACCESSWIRE / March 27, 2024 / Bioz, Inc., a scientific research-focused AI company, and Life Chemicals,…
LUND, SWEDEN / ACCESSWIRE / March 27, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported on…
Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors OverhaulGENEVA, SWITZERLAND / ACCESSWIRE / March 27, 2024 / RELIEF…